Amphastar Pharmaceuticals, Inc. (AMPH) Form 10-Q — Aug 6, 2026
Amphastar Pharmaceuticals posted Q2 2026 net revenues of $183.9 million, up 5% year over year, with diluted EPS of $0.67 versus $0.64 and gross margin improving to 51% from 50%. First-half net income nonetheless fell to $36.8 million from $56.3 million in 2025. Two regulatory/commercial developments stand out: the FDA approved Ipratropium Bromide HFA in February 2026 (launched April), and BAQSIMI hit its first $175.0 million annual net sales milestone in June, triggering a $100.0 million payment to Eli Lilly due in Q3 2026.
Key figures
- Eps
- 0.67
- Revenue
- 183903000
- Net Income
- 30348000
- Total Debt
- 620212000
- Revenue Yoy
- 5%
- Total Assets
- 1743766000
- Cash Position
- 223614000
- Q2 gross margin
- 51%
- Q2 buyback value
- $44.7 million (2,283,375 shares)
- Buyback remaining
- $0.4 million as of June 30, 2026
- Six month revenue
- 355074000
- Six month net income
- 36768000
- Six month diluted eps
- 0.81
- Wells fargo term loan
- 250000000
- Convertible notes rate
- 2.0%
- Six month buyback value
- $74.2 million (3,656,720 shares)
- Buyback authorized total
- 485000000
- Q2 diluted eps prior year
- 0.64
- Convertible notes maturity
- March 15, 2029
- Q2 gross margin prior year
- 50%
- Baqsimi milestone triggered
- 100000000
- Convertible notes principal
- 345000000
- Employee litigation accrual
- 1000000
- Convertible conversion price
- $62.96 per share
- Six month operating cash flow
- 99164000
- Six month net income prior year
- 56315000
- Baqsimi milestone sales threshold
- 175000000
Price after filing
Close on the filing date to close N calendar days later (from $19.90). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.